Antibody therapy for treatment or prevention of infectious diseases

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 4, 2004, Pages 475-481

  Kokai Kun, John F ^a   Mond, James J ^a  

^a Biosynexus Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABTHRAX; ALTASTAPH; ANTIBIOTIC AGENT; ANTIBODY; AUREXIS; AUROGRAB; BACTERIUM ANTIBODY; BSYX A 110; CENTOXIN; CYTOMEGALOVIRUS ANTIBODY; E 5; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MICROGRAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B4; MYCOGRAB; PALIVIZUMAB; POLYCLONAL ANTIBODY; RECEPTOR ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TNX 355; UNCLASSIFIED DRUG; VERONATE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; DRUG MARKETING; HUMAN; INFECTION; INFECTION SENSITIVITY; MYCOSIS; NONHUMAN; VIRUS INFECTION;

EID: 13344281647     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.10.005     Document Type: Review

References (45)

1. R. Lewis Vaccines: Victims of their own success? The Scientist 18 2004 15-19
2. J. Bayry et al. Intravenous immunoglobulin for infectious diseases: Back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol. Sci. 25 2004 306-310
3. M. Berger et al. Therapeutic applications of monoclonal antibodies Am. J. Med. Sci. 324 2002 14-30
4. R.F. Robinson M.C. Nahata Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection Am. J. Health Syst. Pharm. 57 2000 259-266
5. P.J. Sanchez Immunoprophylaxis for respiratory syncytial virus Pedatr. Infect. Dis. J. 21 2002 473-478
6. C.Y. Wang et al. Post exposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex Proc. Natl. Acad. Sci. USA 96 1999 10367-10372
7. R.S. Baltimore et al. Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci J. Immunol. 118 1977 673-678
8. R. Bortolussi G.W. Fischer Opsonic and protective activity of immunoglobulin, modified immunoglobulin and serum against neonatal Escherichia coli K12 Pediatr. Res. 20 1986 175-178
9. G.W. Fischer et al. Opsonic antibodies to Staphylococcus epidermidis: In vitro and in vivo studies using human intravenous immune globulin J. Infect. Dis. 169 1994 324-329
10. I. Gjertsson et al. The impact of FCgamma receptors on Staphylococcus aureus infection Microb. Pathog. 33 2002 145-152
11. K.M. Cunnion et al. Availability of complement bound to Staphylococcus aureus to interact with membrane complement receptors influences efficiency of phagocytosis Infect. Immun. 71 2003 656-662
12. J. Darenberg et al. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome Clin. Infect. Dis. 38 2004 836-842
13. G. Kohler C. Milstein Continuous cultures of fused cells secreting antibody of predetermined specificity Nature 256 1975 495-497
14. T. Vaughan et al. Human antibodies by design Nat. Biotechnol. 16 1998 535-539
15. L.L. Green Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies J. Immunol. Methods 23 1999 11-23
16. K. Tomizuka et al. Double trans-chromosomic mice: Maintenance of two individual human chromosome fragments containing Ig heavy and K loci and expression of fully human antibodies Proc. Natl. Acad. Sci. USA 97 2000 722-727
17. M. Steinitz et al. Continuous production of monoclonal rheumatoid factor by EBV-transformed lymphocytes Nature 287 1980 443-445
18. G.B. Pier et al. A fully human monoclonal antibody (MAb) to Pseudomonas aeruginosa alginate is opsonic and protective against infection with both mucoid and non-mucoid strains Proceedings of the American Society for Microbiology 104th General Meeting 23-27 May, New Orleans, LA 2004 (Abstract D-144)
19. H.R. Hogeboom P. Chames Natural and designer binding sites made by phage display technology Immunol. Today 21 2000 383-390
20. J.R. Adair Engineering antibodies for therapy Immunol. Rev. 130 1992 5-40
21. E. Drewe R.J. Powell Clinically useful monoclonal antibodies in treatment J. Clin. Pathol. 55 2002 81-85
22. H.W. Kim et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine Am. J. Epidemiol. 89 1969 422
23. R.L. Hodinka Human cytomegalovirus (P.R. Murray E.J. Baron M.A. Pfaller F.C. Tenover R.H. Yolken ed.) Manual of Clinical Microbiology (7th edn) 1999 ASM Press 888-899
24. J.J. Wu et al. Vaccines and immunotherapies for the prevention of infectious diseases having cutaneous manifestations Am. Acad. Dermatol. 50 2004 529-532
25. R.A. Good E. Lorenz Historic aspects of intravenous immunoglobulin therapy Cancer 68 6 Suppl. 1991 1415-1421
26. G.W. Fischer et al. Polyvalent group B streptococcal immune globulin for intravenous administration: Overview Rev. Infect. Dis. 12 Suppl. 4 1990 S483-S489
27. T.L. Smith et al. Emergence of vancomycin resistance in Staphylococcus aureus N. Engl. J. Med. 340 1999 493-501
28. K. Hiramatsu et al. The emergence and evolution of methicillin-resistant Staphylococcus aureus Trends Microbiol. 9 2001 486-493
29. L. Weisman et al. Effectiveness and pharmacokinetics of an anti-lipoteichoic acid humanized mouse chimeric monoclonal antibody Proceedings of the Pediatric Academic Societies Meeting May, Baltimore, MD 2001 (Abstract No. 1722)
30. G.W. Fischer Passive immunoprophylaxis of S. aureus and S. epidermidis (anti-LTA) International Symposium on Immunological Approaches against Nosocomial Infections 19-21 November, Veyrier-du-Lac, France 2003 (Abstract 850)
31. L.E. Weisman et al. Safety and pharmacokinetics of an anti-lipoteichoic acid humanized mouse chimeric monoclonal antibody in healthy adults Proceedings of the Pediatric Academic Societies Meeting May, Baltimore, MD 2002 (Abstract No. 1572)
32. L.E. Weisman et al. Safety and pharmacokinetics of a human chimeric anti-staphylococcal monoclonal antibody for prevention of coagulase negative staphylococcal infection in very low birth weight infants: preliminary report Proceedings of the Pediatric Academic Societies' Annual Meeting 3-6 May, Seattle, WA 2003 (Abstract 752553)
33. M. Hook T.J. Foster Staphylococcal surface proteins (V.A. Fischetti R.P. Novick J.J. Ferretti D.A. Portnoy J.I. Rood eds.) Gram-Positive Pathogens 2000 ASM Press 386-391
34. A.E. Hall et al. Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A Infect. Immun. 71 2003 6864-6870
35. J.P. Burnie et al. Aurograb® - a human recombinant antibody for the treatment of MRSA infection Proceedings of the American Society for Microbiology 102nd General Meeting 19-23 May, Salt Lake City, Utah 2002 (Abstract A-72)
36. A.I. Fattom et al. Development of StaphVAX™, a polysaccharide conjugate vaccine against S. aureus infection: From lab bench to phase III clinical trials Vaccine 22 2004 880-887
37. C. Kelly-Quintos et al. Biological characterization of fully monoclonal antibodies to Staphylococcal surface polysaccharide PNAG Proceedings of the American Society for Microbiology 104th General Meeting 23-27 May, New Orleans, LA 2004 (Abstract A-068)
38. M. Subramanian et al. ABthrax (PA mAb)-A novel fully human monoclonal antibody against protective antigen of B. anthracis: Results of a phase 1 single dose-escalation study in healthy human subjects Proceedings of the American Society for Microbiology Biodefense Meting March, Baltimore, MD 2004 (Abstract 158D)
39. N.C. Riedemann et al. The enigma of sepsis J. Clin. Invest. 112 2003 460-467
40. E.J. Ziegler et al. Treatment of gram-negative bacteremia and septic shock with HA-1A, a human monoclonal antibody against endotoxin N. Engl. J. Med. 324 1991 429-436
41. E. Abraham et al. Double-blind randomized controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock. NORASEPT II Study Group Lancet 351 1998 929-933
42. R.C. Matthews et al. Preclinical assessment of the efficacy of Mycograb, a human recombinant antibody against fungal HSP90 Antimicrob. Agents Chemother. 47 2003 2208-2216
43. C.P. Taborda et al. More is not necessarily better: Prozone-like effects in passive immunization with IgG J. Immunol. 170 2002 3621-3630
44. C.A. Irwin et al. Enhancement of human natural killer activity against Cryptococcus neoformans by murine monoclonal antibodies directed against glucuronoxylomannan Proceedings of the American Society for Microbiology 104th General Meeting 23-27 May, New Orleans, LA 2004 (Abstract F-086)
45. H. Xin J. Cutler Genetic instability may explain a shift from protective to non-protective potential of a monoclonal antibody against experimental candidiasis Proceedings of the American Society for Microbiology 104th General Meeting 23-27 May, New Orleans, LA 2004 (Abstract F-094)